- Report
- April 2025
- 93 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- April 2025
- 194 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- April 2025
- 265 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- April 2025
- 283 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- April 2025
- 194 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- April 2025
- 208 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- April 2025
- 88 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- April 2025
- 88 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- April 2025
- 168 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- January 2025
- 250 Pages
Global
From €4550EUR$4,999USD£3,900GBP
- Report
- April 2024
- 183 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- December 2021
Global
From €4414EUR$4,850USD£3,784GBP
- Book
- April 2020
- 272 Pages
- Book
- June 2021
- 592 Pages
- Book
- April 2020
- 336 Pages
- Book
- April 2019
- 816 Pages
- Book
- July 2018
- 832 Pages
- Book
- September 2016
- 680 Pages
- Book
- May 2016
- 288 Pages
- Book
- October 2015
- 520 Pages

The Hepatitis market is a subset of the larger Hepatology market, which focuses on the diagnosis, treatment, and prevention of liver diseases. Hepatitis is a viral infection that can cause inflammation of the liver, and can be caused by a variety of viruses, including hepatitis A, B, C, D, and E. Treatment for hepatitis can include antiviral medications, immunosuppressants, and interferon therapy. Vaccines are also available to prevent hepatitis A and B.
The Hepatitis market is a growing field, with a focus on developing new treatments and therapies to improve patient outcomes. Companies in the market include Gilead Sciences, AbbVie, Merck, Bristol-Myers Squibb, and Novartis. Show Less Read more